836 results about "Niacin" patented technology

The invention describes a pharmaceutical composition and method for treating cancer comprised of A) 2,3-dimethoxy-5-methyl-1,4-benzoquinone and / or B) at least one of wild yam root, teasel root, balm of gilead bud, bakuchi seed, dichroa root, kochia seed, kanta kari, bushy knotweed rhizome, arjun, babul chall bark, opopanax and bhumy amalaki; optionally one or more of frankincense, garcinia fruit, vitex, dragons blood, mace, sage and red sandalwood with at least c) one compound capable of maximizing oxidative mitochondrial function preferably riboflavin or vitamin B2 derivatives, FAD, FMN, 5-amino-6-(5′-phosphoribitylamino)uracil, 6,7-Dimethyl-8-(1-D-ribityl)lumazine, ribitol, 5,6-dimethylbenzimidazole, tetrahydrobiopterin, vitamin B1, lipoic acid, biotin, vitamin B6, vitamin B12, folate, niacin, vitamin C and pantothenate and / or d) at least one lactic acid dehydrogenase inhibitor (preferably 2′,3,4′5,7-pentahydroxyflavone) and optionally f) an alkalizing agent (aloe vera, chlorella, wheat grass, sodium or potassium bicarbonate, potassium) g) an antiproliferative herb (speranskia or goldenseal) and h) a pharmaceutically acceptable carrier.

A dietary supplement of mitochondrial nutrients is designed for relieving stress, preventing and improving stress-related disorders, such as chronic fatigue syndrome, diabetes, age-associated cognitive dysfunction and diseases (Parkinson's and Alzheimer's disease). The supplement composition has the following nutrients: B vitamins (cyanocobalamin 2-1,000 ug, thiamin 1-1,000 mg, niacin 15-2,000 mg, pyridoxine 1-1,000 mg, Pantothenate 5-150 mg, folic acid 400-40,000 ug), alpha-tocopherol 10-800 mg, ascorbic acid 50-10,000 mg, calcium 20-2,000 mg, vitamin A 200-10,000 ug, alpha-lipoic acid 100-1,000 mg, N-acetyl cysteine 100-3,000 mg, L-carnosine 100-9,000 mg, tyrosine 100-9,000 mg, vanillin 10-100 mg, phosphatidylserine 10-800 mg, resveratrol 10-50 mg, dehydroepiandrosterone 1-50 mg, and melatonin 0.1-3 mg, all of which have been individually used experimentally or clinically for relieving stress, preventing and treating age- and stress-related disorders and diseases but no combination of these compounds has been used. Many embodiments also contain at least one adjunct ingredient such as coenzyme Q 10-200 mg, acetyl-L-carnitine 100-2,000 mg, choline 50-1,000 mg, and creatine 100-2,000 mg.

This invention relates to a nutritional intervention composition for enhancing satiety prior to a meal and extending satiety after a meal. The nutritional intervention composition decreases food intake producing weight loss over time. The composition consists of Niacin, Vitamin B6, Calcium, Phosphorous, Magnesium, Chromium, Chitosan, Fenugreek, Ginseng, White willow bark, Garcinia cambogia, Aloe Vera gel powder, Momordica charantia, Griffonia simplicifolia, Lagerstroemia speciosa and Vanadyl sulfate. The invention does not require stimulants or anabolic ingredients. There are three phases of activity within the composition. One, enhanced satiety through elevated serotonin. Two, improved carbohydrate metabolism, reduced blood glucose and slowed gastric emptying. Three, enhanced fiber binding of lipids and excess bile acids.

The invention discloses methods of using cis-epoxyeicosantrienoic acids (“EETs”), inhibitors of soluble epoxide hydrolase (“sEH”), or a combination of an EET and an inhibitor of sEH, to reduce or prevent niacin-induced cutaneous vasodilation (“flushing”) in subjects suffering from this undesirable side effect of receiving therapeutic amounts of niacin.

Methods and compositions are disclosed for enhancing neurogenesis, resolving neuropathy and improving neurological health and functioning using fungal extracts and their active ingredients, including species of mushrooms and mycelia containing psilocybin and psilocin, combined with erinacines and hericenones or fungal extracts containing those active ingredients, with the addition of nicotinic acid. The compositions may optionally be combined with nervine plants.

A nutritional composition for improving blood cholesterol by jointly and simultaneously inhibiting cholesterol absorption, decreasing blood LDL levels, increasing blood HDL levels and interfering with HMG-CoA reductase synthesis or degradation in an individual comprising, therapeutically effective amounts of plant sterols or plant stanols or derivatives thereof, procyanidins, policosanol and niacin or derivatives of niacin is provided. Both a composition and a method are provided by the present disclosure.

Refrigeration-shelf-stable ready-to-feed and concentrated infant formulas prepared through an ultra-pasteurization and / or pasteurization process, comprise per five fluid ounces from about 1.8 to about 6.3 grams of protein; from about 3.3 to about 15.9 grams of fat; from about 300 mg to about 3000 mg of linoleic acid; from about 250 to about 900 IU of Vitamin A; from about 40 to about 180 IU of Vitamin D; from about 0.7 to about 9 IU of Vitamin E; from about 4 to about 24 mcg of Vitamin K; from about 40 to about 300 mcg of Thiamine (Vitamin B1); from about 60 to about 450 mcg of Riboflavin (Vitamin B2); from about 35 to about 180 mcg of Vitamin B6; from about 0.15 to about 0.9 mcg of Vitamin B12; from about 250 to about 3150 mcg of Niacin; from about 4 to about 48 mcg of Folic Acid (Folacin); from about 300 to about 1500 mcg of Pantothenic Acid; from about 1.5 to about 13.2 mcg of Biotin; from about 8 to about 36 mg of Vitamin C (Ascorbic Acid); from about 7 to about 48 mg of Choline; from about 4 to about 18 mg of Inositol; from about 60 to about 234 mg of Calcium; from about 30 to about 159 mg of Phosphorus; from about 6 to about 24 mg of Magnesium; from about 0.15 to about 5.4 mg of Iron; from about 0.5 to about 3 mg of Zinc; from about 5 to about 45 mcg of Manganese; from about 60 to about 270 mcg of Copper; from about 5 to about 75 mcg of Iodine; from about 20 to about 81 mg of Sodium; from about 80 to about 324 mg of Potassium; and from about 55 to about 195 mg of Chloride; wherein the total caloric content is from about 80 kilocalories to about 300 kilocalories per five fluid ounces.

The present invention is directed to the process of preparing a sustained release niacin tablet and the product prepared therefrom.

Methods, systems and formulations for normalizing and improving human body chemistry and the body's natural ability to heal itself. In one embodiment a system including effective amounts of a digestive enzyme, soluble and insoluble fiber, laxative, probiotics, vitamin C, potassium, protease enzymes, lipase, lysine, taurine, proline, choline, inositol, inositol hexaphosphate, policosanol, charcoal, bentonite clay, thyme, ascorbic acid, magnesium citrate, calcium citrate, methylsulfonyl methane, cayenne pepper, magnesium, potassium, ester-c, ginger and niacin, lysine calcium, stevia leaf, citric acid, a tincture of bayberry bark, juniper berries, yam root, cramp bark, golden seal root, fennel seed, uva ursi leaves, ginger root, lobelia herb, catnip herb, and peppermint leaf, golden seal root, Echinacea angustifolia root, ginger root, and licorice root, a tincture of black walnut hulls, venus fly trap, chaparral, wormwood, licorice root, slippery elm, cloves and comfrey root, burdock root, sheep sorrel, rhubarb root, slippery elm, olive leaf and yarrow flower is provided.

A dietary nutritional supplement is designed specifically to address the needs of moderate to heavy alcohol product consumers. The nutritional supplement contains effective amounts of essential components vitamin B2, vitamin B6, vitamin B12 (Cobalamin), vitamin B3 (Niacin), vitamin B1 (Thiamin), Calcium, magnesium, vitamin A, vitamin C (ascorbic acid), folic acid, L-cysteine, L-methionine, Milk Thistle, selenium, dandelion, and Molybdenum.

The present invention relates to a nutritional supplement composition, comprising a therapeutically effective amounts of Vitamin C, Vitamin D3, Thiamin, Riboflavin, Niacin, Vitamin B6, Folic acid, Vitamin B12, Pantothenic acid, Calcium, Magnesium, Zinc, Chromium, Sugar, Protein, Acetyl-L-Carnitine, Dimethylaminoethanol complex, Phosphatidylserine complex, L-Glutamine, N-Acetyl-L-Tyrosine, L-Phenylalanine, Taurine, Methionine, Valine, Isoleucine, 5 Hydroxytryptophan, L-Taurine, N-Acetyl-Tyrosine, N-Acetyl-L-Cysteine, Alpha Lipoic Acid, Alpha Glycerylphosphoricholine complex, Bacopa Monnieri extract, Gingko Biloba extract, Passion flower, Lemon Balm, Gotu Kola, Ashwagandha, Choline Bitartrate complex, Panax Ginseng extract, Turmeric, Organic freeze dried fruit juice blends (concord grape, red raspberry, pineapple, cranberry, acai, pomegranate, acerola cherry, bilberry, lingonberry, black currant, aronia, sour cherry, black raspberry), Organic freeze dried greens blends (barley grass, broccoli, beet, carrot, alfalfa, oat), and Protein digestive enzyme blends (Protease 4.5, peptidase, bromelain, protease 6.0, protease 3.0, L planatrum, B bifidum) in a mixture to provide optimal cognitive function.

Novel antimicrobial products and methods of making and using the same are shown, whereby the products can be used in the same or greater percentages as conventional microbial growth inhibitors without imparting an off-flavor, taste, color or odor to the products in which they are used. The antimicrobial products are formed by reacting azodicarbonamide or an ammonia gas with a compound selected from the group consisting of benzoic acid, sodium benzoate, calcium benzoate, potassium benzoate, acetic acid, sodium diacetate, paraben, niacin, calcium acetate, calcium diacetate, citric acid, lactic acid, fumaric acid, sorbic acid, sodium sorbate, calcium sorbate, potassium sorbate, propionic acid, sodium propionate, calcium propionate, potassium propionate and mixtures thereof. In one embodiment, the product is prepared by placing a layer of azodicarbonamide on a substrate and covering the layer with a gas permeable separator. The antimicrobial compound is then added on top of the separator, and the combination is heated to form the final product. In another embodiment, the product is prepared by exposing the antimicrobial compound to an ammonia gas. The ammonia gas reacts with free acids in the antimicrobial compound to convert the free acids into ammonium salts, thereby eliminating off-flavor and off-odor of the resulting antimicrobial product. The antimicrobial products prepared according to the present invention are suitable for use in foodstuffs, sanitation products, cosmetics, pharmaceuticals, and so forth.

A mineral-fortification system that has a bottle cap, a pouch and a pouch opener. A powder is contained within the pouch, and the powder contains at least one mineral and a redox modulating compound. When the cap is secured onto the opening of a bottle containing a liquid and when the pouch opener is activated, the powder is released from the pouch and mixes with the liquid to form a mineral fortified liquid composition that is fortified with at least one mineral and has a pH between about 2.5 and 9.5. Moreover, the mineral fortified liquid composition has a redox potential that satisfies the following equation:0≧RP−(A−B*pH).In this equation RP is the redox potential in millivolts of the mineral-containing liquid composition, pH is the pH of the mineral-containing liquid composition, A is 400 and B is 20. The mineral is preferably selected from calcium, iron, zinc, copper, manganese, iodine, magnesium, and mixtures of these. Moreover, the mineral-fortified liquid composition may preferably be substantially free of flavor or sweetener compounds. Even more preferably, the liquid composition has no metallic taste or after-taste, a Hunter colorimetric “b” reading of less than 5.0, and an NTU turbidity value of less than 5.0. The mineral-fortified liquid composition may optionally contain other nutrients and vitamins, for example, vitamin A, vitamin C, vitamin E, niacin, thiamin, vitamin B6, vitamin B2, vitamin B 12, folic acid, selenium, pantathonic acid, and iodine.

The present disclosure provides for novel krill oil-based compositions, method of administration and method of manufacture which provide for the treatment and prevention of cardiovascular disease, including the reduction of one or more significant risk factors involved with cardiovascular disease. The active ingredients of the composition include krill oil, combined in one embodiment with niacin, and combined in an alternate embodiment with polymethoxylated flavones (PMFs), and combined in yet another embodiment with Cissus quadrangularis, and combined in a further embodiment with Gynostemma pentaphyllum.

The invention discloses a labeled 99mTc hydrazino-nicotinamide-dioxodecoyl-folic acid coordination compound with a general formula of 99mTc(HYNIC-NOON-FA)(Tricine)(L). In the structural formula, L is triphenyl sodium phosphate or triphenyl sodium photrisulfonic acid, wherein 1,8-diamido-3,6-octane dioxide is used as a connecting chain for generating a hydrazino-nicotinamide-3,6-dioxodecoyl-folic acid coupler respectively with folic acid and hydrazino-niacin through amido bonds and coordinating with oxygen atoms and phosphorus atoms in a co-ligand Tricine and an L molecule and 99mTc, and the 99mTc(HYNIC-NOON-FA)(Tricine)(L) coordination compound is obtained through two steps of: (a) synthesizing the hydrazino-nicotinamide-3,6-dioxodecoyl-folic acid coupler used as a ligand; and (b) labeling the 99mTc-hydrazino-nicotinamide-dioxodecoyl-folic acid coordination compound. The coordination compound has the advantages of high radiochemical purity, good stability, high tumor intake, good retention, low non-target organ background and clear tumor SPECT (Single Photon Emission Computed Tomography) development and can be prepared into a novel 99mTc labeled folic acid receptor tumor developer widely applied to the technical field of radioactive pharmaceutical chemistry and nuclear medicine.

Provided, among other things, is a formulation or kit comprising: (a) a pharmaceutically effective dosage of one or more a glucose-level-controlling bioactive agents selected from an α-glucodase inhibitor, sulfonylurea, meglitinide, thiazolidinediones, biguanide, insulin, dual PPARα / γ agonist, PPARγ agonist or insulin secretagogue; and (b) a pharmaceutically effective dosage of (i) one or more of an antihypertensive bioactive agent selected from an ACE inhibitor, calcium channel blocker, beta blocker, angiotension II receptor antagonist or diuretic, or (ii) one or more of an anti-dyslipidemia bioactive agent selected from a HMG-CoA reductase inhibitor, bile acid sequestrant, fibric acid derivative, sterol, cholesterol absorption inhibitor, MTP inhibitor or nicotinic acid derivative; wherein: in the case of (i) a combination of a first bioactive agent of group (a) that is metformin with a second bioactive agent of group (b), or (ii) a combination of a first bioactive agent of group (a) that is a thiazolidinedione or dual PPARα / γ agonist with an angiotension II receptor antagonist, one or more of the following applies: (I) one of the first bioactive agent or the second bioactive agent is formulated for sustained release, and the other is formulated for immediate release, each formulated for once-a-day dosing; or (II) the co-formulation or kit comprises (A) a biguanide and a thiazolidinedione and (B) one or more group (b) bioactive agents.

The invention provides a novel pig feed formula which relates to an animal feed formula, in particular to a pig feed formula. The feed comprises the following ingredients in proportions: 40-75% of corn, 5-28% of soybean meal, 0-6% of peanut meal, 0.05-0.45% of table salt, 0-0.4% of sodium sulfate, 0-0.7% of lysine hydrochloride, 0-1.1% of lysine sulfate, 0-1.2% of powdered 50% choline chloride, 0.05-5% of mineral trace element premix, vitamin premix 50-1000grams / ton, phytase feed additive 0-1000grams / ton, bacillus licheniformis powdered preparation 50-2000grams / ton, and niacin / chromium picolinate feed level / food level / medicine level additive 50-500grams / ton. By adopting the novel pig feed formula, the back fat of the fattened pigs for sale is lower than 1cm, the daily weight gain of the fattened pigs above 60-100kg for sale reaches or exceeds 1000 grams in the late fattening stage, and the consumption-weight gain ratio is lower than 2.7.

The invention relates to compound premix feed for laying hens, which comprises 3 to 9 kg of manganous sulfate, 3 to 7 kg of zinc sulfate, 3 to 7 kg of ferrous sulfate, 0.6 to 1.4 kg of copper sulphate, 12 to 18 kg of choline chloride, 7 to 11 kg of lysine, 26 to 34 kg of methionine, 1.6 to 2.4 kg of phytase, 400 to 461 kg of calcium carbonate, 80 to 120 kg of calcium hydrophosphate, 300 to 360 kg of fish meal, 45 to 75 kg of common salt, 0.20 to 0.44 kg of vitamin A, 0.06 to 0.14kg of vitamin D3, 0.52 to 1.12 kg of vitamin E, 0.047 to 0.1 kg of vitamin K3, 0.026 to 0.056 kg of vitamin B1, 0.177 to 0.33 kg of vitamin B2, 0.078 to 0.145 kg of vitamin B6, 0.025 to 0.058 kg of vitamin B12, 0.02 to 0.03 kg of folic acid, 0.008 to 0.018 kg of biotin, 0.3 to 0.674 kg of nicotinic acid, 0.11 to 0.245 kg of calcium pantothenate, and 1.2 to 3.83 kg of rice hull powder. The laying hens fed by the premix feed have high laying rate, and keep long period of peak time of laying eggs reaching 6-9 months. The ratio of the feed to the egg is as low as 2.0-2.1:1.

A composition is provided which contains policosanol and niacin and / or niacin derivatives and which may be used for treating and or reducing hypercholesterolemic diseases, total cholesterol, LDL-cholesterol, LDL / HDL ratio, Lp(a), triglycerides, coronary heart disease (heart attacks and strokes), inflammation, immunoregulatory diseases, cardiovascular diseases, deep vein thrombosis, anxiety, depression and / or neurodegenerative disorders, and / or raise HDL cholesterol in humans and animals. The method comprises administering policosanol and niacin and / or niacin derivatives which together effectively lower the LDL / HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to niacin and / or niacin derivatives.

The invention relates to fatty acid niacin conjugates; compositions comprising an effective amount of a fatty acid niacin conjugate; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid niacin conjugate.

The present invention relates to compositions without added iron and methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the method involves administering to an individual a composition comprising carotenoids, vitamin E, vitamin D, vitamin C, thiamine, riboflavin, niacin, folic acid, pyridoxine, biotin, pantothenic acid, cobalamin, magnesium, manganese, zinc, selenium, chromium, copper, alpha lipoic acid, and lutein, wherein the composition is free of added iron.

The present disclosure provides for novel krill oil-based compositions, method of administration and method of manufacture which provide for the treatment and prevention of cardiovascular disease, including the reduction of one or more significant risk factors involved with cardiovascular disease. The active ingredients of the composition include krill oil, combined in one embodiment with niacin, and combined in an alternate embodiment with polymethoxylated flavones (PMFs), and combined in yet another embodiment with Cissus quadrangularis.

This invention discloses a method of use for a topical herbal formulation alone or in combination with oral administration of niacin (preferably a flush preparation) to prevent and / or treat dyshidrosis (pompholyx) and related skin diseases. The formulation may also be used to treat contact dermatitis, eczema, palmoplantar pustulosis and skin infections incurred by invasive pathogens such as mold, fungus and bacteria. The formulation is comprised of plant extracts and niacin, that when combined yield an effective multi-faceted pharmaceutical approach to treating dry skin disorders. The active ingredients within the formula include a combination of dry, aqueous, acid and alcohol extracts of black walnut hull (Juglans nigra), wormwood (Artemisia absinthium), tumeric rhizome (Curcuma longa), garlic (Allium sativum), two or more herbal antibacterial agents from the group consisting of chamomile (Matricaria Chamomile), licorice root (Glycyrrhiza glabra), St Johns wort (Hypericum perforatum), clove (Syzygium aromaticum), nutmeg (Myristica fragans), ginger (Zingiber officinale), frankincense (Boswellia carteri) and myrrh (Commiphora molmol), further combined with aloe vera and niacin.

A formulation comprising cinnamon and an active compound such as creatine, a statin drug, niacin, lipoic acid and / or Red Yeast Rice is disclosed. The cinnamon aids in moving the active compound into cells making the active compound more effective as compared to its administration in the absence of cinnamon. Methods of treatment including methods of reducing cholesterol levels, building muscle and treating diabetes are enhanced by the co-administration of cinnamon with another compound.

The invention relates to a pig fattening feed and belongs to the technical field of animal feeds. The pig fattening feed mainly solves the technical problems of overmuch fatty pork, high cost and low income which are caused by adopting concentrated feed to fast fatten pigs when the pigs are fattened before being taken to markets in the conventional feedlots. The pig fattening feed is prepared by mixing the following raw materials in a certain proportion: corn flour, soybean meal, bran, rock flour, calcium hydroxide, salt and premix, wherein the premix consists of vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin D3, vitamin E, vitamin K3, biotin, niacin, calcium pantothenate, folic acid, choline chloride, ferrous sulfate, copper sulfate, manganese sulfate, zinc sulfate, potassium iodide and sodium selenite. The pig fattening feed has the advantages of high feed utilization efficiency, low cost and high income.

The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.